Home » Event Agenda » Agenda


Cell and Gene Therapy World Congress 2024 Europe

"Driving Innovation, Addressing Significant Unmet Medical Needs, and Ultimately Improving Patient Outcomes"

8th - 9th July 2024, Hilton London Kensington, LONDON, UK


Cell and Gene therapies are forms of personalised, regenerative medicine. Described as the most innovative, promising and life-changing new categories of medicines whose full potential is only just beginning to emerge. They are cutting-edge and rapidly progressing fields of Biological Therapies. Also known as “Advanced Therapy Medicinal Products”, they involved the use of cells, tissues and genes to treat, prevent or potentially cure and eliminate complicated health conditions and difficult to treat diseases. These therapies promise life-changing treatments for a broad spectrum of complex diseases ranging from genetic conditions to cancers. Both approaches offer the potential to diminish the fundamental cause of genetic and acquired diseases by substituting the missing protein or cells causing the disease’s symptoms. Cell and gene therapies may offer longer lasting effects than traditional medicines. Convergence of advanced biotechnology, precision medicine, and expertise in manufacturing has facilitated the way for these therapies to become a reality, with remarkable successes observed in conditions such as cancer and genetic disorders.

Cell and Gene therapy has transformed the healthcare and biopharma industry by storm. Currently, after around 40 CGT launches across the EU and US, the market is worth around EUR 4.5 billion. A similar number are expected to be approved by 2028, when sales are projected to rise to EUR 19.2 billion. The development of biological therapies is rapidly expanding, however, commercialisation of this treatment poses different challenges to research and development, authorisation, manufacturing, accessibility, and ensuring safety throughout the lifecycle of the product.

The two-day Congress will provide an interactive, cutting edge, and comprehensive discussions in collaborative format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies, and concepts to help you gain access to the booming CGT market.

We are putting together an agenda that focuses on “driving innovation, addressing significant unmet medical needs, and ultimately improving patient outcomes”. We are gathering high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the CGT World Congress 2024!

WHO SHOULD ATTEND?                                 
This congress is specially created for valued stakeholders in the Cell & Gene therapy community: Presidents, Heads/Chiefs, VPs, Directors, and Managers in the area of:

• Clinical Research Organizations
• Research and Development
• Personalised Medicine
• Regenerative Medicine
• External R&D Innovation
• Innovative Medicine
• Rare and Ultra-Rare Diseases
• Cell and Gene Therapy
• Translational Science
• Molecular Geneticist
• Program Management
• Patient and Patient Groups
• Public Affairs
• Medical Affairs
• Regulatory Affairs
• Market Access
• Pricing and Reimbursement
• Health Economics Outcomes Research
• Commercial Development
• Investments and Funding
• Product Specialist
• Global Strategic Services
• Business Planning and Operations
• Pharmacies
• Academia

  • Gain the latest insights to successfully navigate the complex access landscape of CGT
  • Explore ways on how to strategically steer the state-of-the-art technologies in cell and gene therapies
  • Understand approaches in advancing research and drug development
  • Strategies in making HTAs more CGT focused
  • Tackling barriers in regulatory compliance: discussions to streamline the process
  • Know how to engage early with regulators and payers to enable swift roll-out of new therapies for the benefit of the patients
  • Learn the production process which is crucial for new players entering the field
  • Robust processes essential for ensuring performance, which helps prevent batch failures and associated costs
  • Scalable technologies to manufacturing and to meet increased patient demand
  • Have a meaningful conversation on how to improve access efficiently to innovative treatment to reach patient in a shorter period of time
  • Find out if CGTs offer long-term value for money to manufacturer, regulators and payers
  • Addressing the challenges associated with pricing and market access
  • Network and collaborate with key stakeholders, regulators, academia, HTAs and payers


"Driving Innovation, Addressing Significant Unmet Medical Needs, and Ultimately Improving Patient Outcomes"

Day 1 - Monday 8th July 2024


  • Latest trends and valuable insights to drive innovation and remain competitive
  • Cutting-edge technologies revolutionizing treatment paradigms
  • Aligning with international regulatory standards in order to support the broadest possible patient access.
  • Ensuring affordability and accessibility of these therapies
  • Key drivers for attracting investment
  • Pricing models and reimbursement strategies
  • Introduction
  • Demonstrating the UK’s continuous strength in the cell and gene therapy sector.
    Challenges facing companies in this space
    Collaborative work and initiatives to guarantee continued growth of the sector
    Lessons learned and strategies to unlock the full potential of this developing field
  • Brief overview and important breakthoughs of the EU HTA regulation
  • Implications to drug developer of ATMPs
  • Potential effect on clinical development plans, commercialization strategies, and patient access
  • What are the opportunities the EU market presents
  • Proactive preparations needed for upcoming changes
  • Understanding the key logistics requirements in operationalizing Cell and gene therapy trials
  • Comprehensive strategies to logistics management
  • Addressing a whole range of intricacies across all types of CAGT assets
  • Significance of stakeholder partnerships to optimize supply chain and enhance patient experience
  • Ways to navigate and succeed in this promising yet competitive sector
    Strategic portfolio assessments and management critical to success
    Importance of robust clinical pipeline to attract interest from investors
    Considering the complexity of the manufacturing process, supply chain requirements of each, along
    with the required regulatory pathway to market.
  • Improving clinical trials, strengthening regulatory authorities
  • Foster use of health data for innovation
  • Promoting innovative research projects
  • Reimbursement for gene therapies and ATMPs


  • An overview of diverse synthetic receptor systems being used to reprogram therapeutic cells and their wide applications in biomedical research
  • Cutting edge synthetic receptor systems at the forefront
  • Strategies to design, construct and improve synthetic receptors
  • Expanding landscape of therapeutic applications of the synthetic receptor systems
  • Current challenges in their clinical translation
  • Scientific and regulatory considerations when planning for the development of genetically altered cell therapy products
  • Framework for approaching these projects from a pre-clinical perspective
  • Recent trends across projects in the pre-clinical aspects of cell therapy development
  • Current landscape of CAR-T cells manufacturing
  • Challenges limiting production capacity
  • Latest technical developments in GMP production platform design
  • Challenges associated with translation of new scientific developments into clinical products for patients
  • Challenges in integrating robotics to automate parts of the development process
  • Key standards to develop automation technology that would allow large scale development efficiently
  • Advances in robotics
  • Acknowledging the scaling-up challenge is a critical point in the development of cell and gene therapies
  • When does aspects of scale up and manufacturing ought to be considered
  • Importance of integrating data driven approaches to address current hurdles
  • Current development in scalable technologies and automation
  • Advancements that pave the way for more therapies to successfully move from development, to clinical trials, and on to commercialisation.
  • State of continuous process implementation and some ongoing challenges.
  • Technological advancements that helps drive batch productivity and reduce the costs for patients
  • Improving the design and efficiency of facilities to focus on quality, getting into manufacturing quicker
  • Lowering the overall cost of goods and the amount of raw materials used
  • Lessons learned and best practices


"Driving Innovation, Addressing Significant Unmet Medical Needs, and Ultimately Improving Patient Outcomes"

Day 2 - Tuesday 9th July 2024


  • The importance of stakeholder engagement: perspectives across different functions
  • Creating a CGT platform: stakeholder engagement as a tool to support not only the development/commercialization of specific assets, but to build a sustainable platform
  • How national level activities can impact on patient access to ATMPs
  • Further national level collaboration between academic, clinical and industrial players is necessary to overcome the existing hindrances and boost further development of ATMPs in Europe.
  • Addressing the lack of easily accessible and understandable information about advanced therapies
  • Ensuring timely access to the communities who would most benefit from the products.
  • Tackling patient concerns through technology & innovation approaches
  • Ways to reduce burden of treatment by reducing disruption to patients lives
  • Demonstrating value to payers
  • The significance of rationalizing clinical trials to reduce logistical and financial burdens for participants
  • Leveraging technology to enhance access to treatment and specialist care
  • Data-driven strategies to make informed decisions
  • Patient-centred approach for better experience and outcomes
  • Breakthroughs being made to deliver these innovative therapeutic options to cancer patients.
  • Example of Cell therapies revolutionizing cancer treatment
  • Specific approaches used to advance cell and gene therapies for cancer
  • Collaborations to advance cell and gene therapies for cancer
  • Unique public-private partnership that has increased the access to new treatment options for patients
  • Promote further innovation in clinical research using the strengths of the partnership
  • Align potentially conflicting organizational cultures to maximize efficiencies and share project leadership
  • Utilize a precision medicine master protocol to bring cutting-edge advances
  • Allow for broader patient access and clinical trials that are more inclusive than standard industry-run trials
  • Significant milestones in the development of gene therapy medicinal products that have facilitated the treatment of a significant number of rare diseases
  • Bottlenecks and potential solutions that can improve access to gene therapy for rare diseases.
  • Stakeholders engagement to bring about changes to improve access to gene therapy


  • Circumventing operational complexities and regulatory barriers
  • Consider near- and longer-term implications and opportunities to influence the design of the model
  • Ability of the model to reduce costs and improve access
  • Monitoring the development to better understand successful contracting arrangements
  • Assess how potential therapeutic area expansion may impact pricing, reimbursement, and access for other gene therapy products.
  • Past (learnings…)
  • Benefit Structures / Cost / Contracting (e.g., Outcomes Based)
  • Evidence & its Evaluation
  • Special Considerations (e.g.,
    – Dealing with surrogate endpoints
    – Modifications & Flexibilities for Evaluation of Rare Diseases)
  • Current landscape
  • Existing innovative contracting with gene therapies
  • How to overcome key challenges to innovative payment models.
  • Leveraging real-world evidence to define outcome measures
  • Implications to gene therapy manufacturers
  • Breakthroughs and innovations in research and development
  • Implementing next-generation technologies
  • Novel pricing and market access strategies pharma will employ to increase patient access
  • Various CGTs in the pipeline
  • What will the next decade hold for these life-changing therapies?
Scroll to Top